Mylan gains tentative OK on generic Benicar HCT
This article was originally published in Scrip
The US FDAhas granted tentative approval to Mylan Laboratories’ ANDA for a generic version of Daiichi Sankyo's antihypertensive Benicar HCT (olmesartan medoxomil/HCTZ tablets) in three strengths. The product had annual US sales of about $535 million for the 12 months ending June 30th, and Mylan believes it has first-filer status and thus a potential 180 days of market exclusivity upon final FDA approval. Mylan's ANDA, filed in February 2007, contains a paragraph IV certification that the US olmesartan patent, expiring in April 2016, is invalid or will not be infringed. Daiichi Sankyo sued for infringement last year, and the patent litigation continues. Separately, Mylan gained tentative approval for its generic version of Sanofi-Aventis's Uroxatral ER (alfluzosin HCl extended release tablets), which had US sales of $168 million for the 12 months ending June 30th.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.